RBC Capital Maintains Sector Perform on Sage Therapeutics, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Sage Therapeutics (NASDAQ:SAGE) and lowered the price target from $22 to $21.
November 08, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital has maintained its 'Sector Perform' rating on Sage Therapeutics and lowered the price target from $22 to $21.
The lowering of the price target by RBC Capital indicates a less optimistic outlook for Sage Therapeutics, which could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100